They share common, highly desirable properties with their endogenous AMP predecessors, including a rapid kill time and activity against a broad range of fungal, bacterial and polymicrobial ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...

"For decades, clinicians have relied on a handful of antifungal classes, with few mechanisms of action and significant limitations due to spectrum of activity, drug toxicities, or drug-drug ...

With the addition of echinocandins to the antifungal spectrum, clinicians should have more options for effective therapy of IC. However, owing to limited prospective data on these newer choices ...

T he discovery of a new preclinical compound with strong antifungal activity against multidrug-resistant pathogens is ...